IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Open Access
- 15 September 1997
- journal article
- Published by American Society of Hematology in Blood
- Vol. 90 (6) , 2188-2195
- https://doi.org/10.1182/blood.v90.6.2188
Abstract
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). TheKeywords
This publication has 31 references indexed in Scilit:
- High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaBlood, 1996
- Phase I Trial of an Anti-CD19 Deglycosylated Ricin A Chain Immunotoxin in Non-Hodgkinʼs LymphomaJournal of Immunotherapy, 1995
- Treatment approaches to the low-grade lymphomasBlood, 1994
- A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapyBlood, 1993
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cellsBlood, 1992
- Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferonBlood, 1989
- Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood, 1987
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982